MX2013011589A - Metodos y composiciones para tratar enfermedad de parkinson. - Google Patents

Metodos y composiciones para tratar enfermedad de parkinson.

Info

Publication number
MX2013011589A
MX2013011589A MX2013011589A MX2013011589A MX2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A
Authority
MX
Mexico
Prior art keywords
disease
compositions
methods
treating parkinson
treating
Prior art date
Application number
MX2013011589A
Other languages
English (en)
Inventor
William C Shakespeare
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2013011589A publication Critical patent/MX2013011589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Abstract

La presente invención describe métodos y composiciones para tratar o prevenir la enfermedad de Parkinson, administrando un compuesto de la Fórmula (I): o una sal, solvato o hidrato farmacéuticamente aceptable del mismo, en donde las variables son tal como se define en la presente invención.
MX2013011589A 2011-04-07 2012-04-06 Metodos y composiciones para tratar enfermedad de parkinson. MX2013011589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472961P 2011-04-07 2011-04-07
PCT/US2012/032544 WO2013101281A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating parkinson's disease

Publications (1)

Publication Number Publication Date
MX2013011589A true MX2013011589A (es) 2013-12-16

Family

ID=48698489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011589A MX2013011589A (es) 2011-04-07 2012-04-06 Metodos y composiciones para tratar enfermedad de parkinson.

Country Status (11)

Country Link
US (1) US20140066434A1 (es)
EP (1) EP2694066A1 (es)
JP (1) JP2014513078A (es)
KR (1) KR20140022062A (es)
CN (1) CN103596568A (es)
AU (1) AU2012363094A1 (es)
BR (1) BR112013024169A2 (es)
CA (1) CA2832465A1 (es)
EA (1) EA201391486A1 (es)
MX (1) MX2013011589A (es)
WO (1) WO2013101281A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) * 2012-12-13 2016-05-05 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015076213A1 (ja) * 2013-11-22 2015-05-28 独立行政法人国立成育医療研究センター 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ－ｐｄｇｆｒｂ
WO2015085973A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
US10870647B2 (en) 2016-06-20 2020-12-22 Daegu-Gyeongbuk Medical Innovation Foundation Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
KR20200006495A (ko) * 2018-07-10 2020-01-20 보로노이바이오 주식회사 N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
WO2020015615A1 (zh) * 2018-07-17 2020-01-23 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2020214999A1 (en) * 2019-04-17 2020-10-22 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法
EP4105217A4 (en) * 2020-02-28 2023-09-06 Daegu-Gyeongbuk Medical Innovation Foundation 3-((8-(1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A PYRIDINE-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION USING IT AS AN ACTIVE INGREDIENT
EP4324833A1 (en) 2021-04-13 2024-02-21 Shenzhen Newdel Biotech Co., Ltd. Alkynylphenylbenzamide compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila

Also Published As

Publication number Publication date
KR20140022062A (ko) 2014-02-21
JP2014513078A (ja) 2014-05-29
US20140066434A1 (en) 2014-03-06
BR112013024169A2 (pt) 2016-12-06
CA2832465A1 (en) 2013-07-04
WO2013101281A1 (en) 2013-07-04
EP2694066A1 (en) 2014-02-12
CN103596568A (zh) 2014-02-19
AU2012363094A1 (en) 2013-09-19
EA201391486A1 (ru) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
PH12019500480A1 (en) Pyridine compound
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
PH12017501426A1 (en) Derivatives of betulin
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MX2011009796A (es) Inhibidores de la cinasa pi3.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IN2014KN00948A (es)
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
WO2013040227A3 (en) Therapeutic compounds
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MX345264B (es) Derivado de azol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal